Breaking Down Neurocrine Biosciences: 8 Analysts Share Their Views
Portfolio Pulse from Benzinga Insights
Neurocrine Biosciences (NASDAQ:NBIX) received mixed ratings from 8 analysts, with a shift towards a more neutral stance in the last 30 days. The average 12-month price target is $140.88, indicating a 7.21% increase from the previous target. The company's financials show strong growth and profitability, with a revenue growth rate of 28.59% and a net margin of 16.66%. Analysts from firms like Wells Fargo, Goldman Sachs, and Barclays have raised their price targets, reflecting optimism about the company's future performance.
February 08, 2024 | 2:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Neurocrine Biosciences has received mixed analyst ratings but with a positive outlook on its 12-month price target, indicating a potential increase in stock price. The company's strong financial performance, including a significant revenue growth and high net margin, supports a bullish perspective.
The increase in the average 12-month price target for NBIX, along with the company's strong financial performance, suggests a positive short-term impact on its stock price. Analysts' upgrades and positive ratings reflect confidence in the company's future, likely influencing investor sentiment and stock performance positively.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100